Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBT Margin (2016 - 2025)

Bio-Techne has reported EBT Margin over the past 17 years, most recently at 17.16% for Q4 2025.

  • Quarterly results put EBT Margin at 17.16% for Q4 2025, up 273.0% from a year ago — trailing twelve months through Dec 2025 was 2.25% (down 1237.0% YoY), and the annual figure for FY2025 was 0.96%, down 1413.0%.
  • EBT Margin for Q4 2025 was 17.16% at Bio-Techne, up from 16.75% in the prior quarter.
  • Over the last five years, EBT Margin for TECH hit a ceiling of 5185.8% in Q3 2022 and a floor of 61.09% in Q2 2022.
  • Median EBT Margin over the past 5 years was 17.53% (2025), compared with a mean of 269.44%.
  • Biggest five-year swings in EBT Margin: surged 515965bps in 2022 and later crashed -516790bps in 2023.
  • Bio-Techne's EBT Margin stood at 32.0% in 2021, then dropped by -24bps to 24.46% in 2022, then plummeted by -50bps to 12.25% in 2023, then increased by 18bps to 14.43% in 2024, then rose by 19bps to 17.16% in 2025.
  • The last three reported values for EBT Margin were 17.16% (Q4 2025), 16.75% (Q3 2025), and 34.6% (Q2 2025) per Business Quant data.